The Immune Deficiency Foundation (IDF) commissioned a national survey of the treatment experiences and preferences of patients with primary immune deficiency diseases in the fall and winter of 2002. A total of nearly 1,200 patients with primary immune deficiency diseases with were being treated with intravenous immunoglobulin (IVIG) therapy, completed an eight-page, self-administered questionnaire as part of the survey.